NEW YORK (Reuters Health) Aug 30 – The experimental weight-loss drug lorcaserin may spur modest weight loss without the heart risks of some older drugs, a new clinical trial confirms — though whether the medication will ever reach the market remains up in the air.
路透社報導,減肥新藥lorcaserin可以有減肥的效果,但卻沒有心臟的問題。
基本上這藥屬於selective 5-hydroxytryptamine (5-HT)(2C) receptor agonist, 閱讀全文〈減肥新藥lorcaserin的現況〉